Skip to main content
Funded Studies

Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids

Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report marked discrepancies in alpha-synuclein levels in biological fluids. In addition, our previous studies, funded by MJFF, showed that most of the antibody-based tests used in clinical studies do not detect all of the relevant alpha-synuclein species. We have identified and characterized three commercially available alpha-synuclein-specific antibodies that are not thrown off by the most common alpha-synuclein modifications and therefore represent better tools for capturing and quantifying the total amount of alpha-synuclein.

Hypothesis: Using the antibodies that we identified and characterized for their ability to detect forms of alpha-synuclein that include those with the most common protein modifications, we propose to develop and validate a robust method for detecting and quantifying total alpha-synuclein in human biological fluids.

Study Design: In this study, we will first further characterize the three lead antibodies to evaluate their capacity to recognize different aggregated conformations of alpha-synuclein and assess their specificity when exposed to complex biological materials. We will then determine the suitability of lead antibodies for use in an assay and develop a sensitive test using the most suitable antibody pair. Lastly, we will technically characterize and validate our antibody-based immunoassay using plasma and cerebrospinal fluid from a cohort of people with PD and healthy controls.

Impact on Diagnosis/Treatment of Parkinson’s disease: Successful development of this assay will enable development of alpha-synuclein as a useful diagnostic biomarker of disease progression for PD, more accurate assessment of therapies that target alpha-synuclein and discovery of novel biomarkers based on the ratios of specific forms of alpha-synuclein to total alpha-synuclein.


  • Lara Petricca, MSc

    Epalinges Switzerland

  • Mohamed-Bilal Fares, PhD, MBA

    Epalinges Switzerland

  • Hilal A. Lashuel, PhD

    Lausanne Switzerland

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.